Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Robert W Mutter
VOICE-AE: automated CTCAE scoring from ambient clinical audio using speech recognition and large language models
Abstract Treatment-related adverse event documentation is labor-intensive and subject to inter-observer variability. We developed and evaluated VOICE-AE, a multi-stage pipeline integrating automatic speech recognition, speaker diarization and large language models (LLMs) for automated extraction and grading of Common Terminology Criteria for Adverse Events (CTCAE) toxicities from clinician-patient audio recordings.
Targeting SYK enhances responses to radiotherapy and PD-1 blockade with myeloid immune remodeling in breast cancer
Abstract Introduction: Spleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase involved in immune signaling and has been implicated in tumor-intrinsic resistance to DNA-damaging therapies. Although SYK activity has been associated with poor outcomes in triple-negative breast cancer (TNBC), its role in resistance to combined radiotherapy and immune checkpoint blockade remains unclear.
Proton Radiation for Locally Advanced Breast Cancer: Evolution and Techniques
Keywords proton therapy breast cancer locally advanced breast cancer regional nodal irradiation pencil beam scanning cardiac sparing contouring Get full text access Log in, subscribe or purchase for full access. References 1. Lalani, N. ∙ Alqarni, S. ∙ Jimenez, RB. The Potential of Proton Therapy for Locally Advanced Breast Cancer: Clinical and Technical Considerations Curr Oncol. 2023; 30(3):2869-2878 2. MacDonald, S.M. ∙ Patel, S.A. ∙ Hickey, S. ...
Dose–LET Interactions Predict Capsular Contracture After Proton Postmastectomy Radiation Therapy
Figure 3 (a) Regression coefficient p-value color map derived from the generalized linear mixed-effects regression (GLMER) models for all DLVH indices. Iso-p-value lines of 0.01and 0.05 were contoured in the color map. BH-corrected q-values across the full dose–LETd plane are reported in Supplementary Figure S3.
Less Isn't Simple: Insights From Postmastectomy Radiotherapy Deintensification Trials
1 and BIG 2-04 MRC SUPREMO (SUPREMO)2 trials were eagerly anticipated as potential milestones in addressing this unmet need and have been hailed by some as practice-changing. Here, we examine the clinical and statistical considerations underlying these trials as a framework for evaluating efforts to deintensify radiotherapy.
Redox-driven ADAR1 activation promotes Okazaki fragment maturation and DNA replication integrity - Nature Structural & Molecular Biology
Abstract Okazaki fragment maturation requires efficient removal of RNA primers to form a continuous lagging strand, yet how mismatched primers introduced by error-prone primase are corrected remains unresolved. Here, we show that physiological levels of reactive oxygen species (ROS) initiate a redox-dependent mechanism that drives ADAR1-mediated adenosine-to-inosine (A-to-I) editing.
Dose de-intensified 3-day photon, proton, or brachytherapy: a nonrandomized controlled partial breast irradiation trial
1Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA 2Division of Biostatistics and Clinical Trials, Department of Quantitative Health Sciences, Mayo Clinic, Phoenix, AZ, USA 3Department of Surgery, Mayo Clinic, Rochester, MN, USA 4Division of Medical Oncology Mayo Clinic, Rochester, Minnesota 5Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona 6Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida 7Department of Radiation Oncology, Samsung Medical...
Minibeam Radiation Therapy Treatment (MBRT): Commissioning and First Clinical Implementation
1. Griffin RJ, Ahmed MM, Amendola B, Belyakov O, Bentzen SM, Butterworth KT, Chang S, Coleman CN, Djonov V, Formenti SC, Glatstein E, Guha C, Kalnicki S, Le QT, Loo BW, Jr., Mahadevan A, Massaccesi M, Maxim PG, Mohiuddin M, Mohiuddin M, Mayr NA, Obcemea C, Petersson K, Regine W, Roach M, Romanelli P, Simone CB, 2nd, Snider JW, Spitz DR, Vikram B, Vozenin MC, Abdel-Wahab M, Welsh J, Wu X, Limoli CL. Understanding High-Dose, Ultra-High Dose Rate, and Spatially Fractionated Radiation Therapy.
Repeat sentinel lymph node surgery for locally recurrent breast cancer after prior mastectomy
REFERENCES 1, , , et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005; 23(30): 7703-7720. 2, , , et al. Use of reoperative sentinel lymph node biopsy in breast cancer patients. J Am Coll Surg. 2008; 207(1): 57-61. 3, , , , . Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg. 2015; 150(1): 9-16. 4 National Comprehensive Cancer Network. Breast Cancer.
Proton beam therapy shortens breast cancer treatment, creating access for more patients
Source/Disclosures Disclosures: NCI funded this study. Mutter reports serving as the co-chair of the Breast Cancer Subcommittee of the Particle Therapy Cooperative Group. None of the other authors report relevant financial disclosures. You've successfully added Hematology Oncology: Breast Cancer to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later.
Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial
Research in context Evidence before this study We searched PubMed and abstracts from major international oncology, radiation oncology, and breast cancer congresses, such as the American Society for Radiation Oncology and the San Antonio Breast Cancer Symposium, for phase 3 randomised postmastectomy radiotherapy (PMRT) trials published in English between Jan 1, 1980, and Jan 1, 2023. We used search terms such as “hypofractionation”, “breast cancer”, and postmastectomy radiotherapy”.
Study Results Show Shorter Radiation for Breast Cancer is ‘Worthy of Further Study’
Optimizing the dose and fractionation regimen are some of the next steps in further developing postmastectomy radiation therapy in breast cancer, according to an expert from Mayo Clinic. During the 2022 San Antonio Breast Cancer Symposium (SABCS), CancerNetwork® spoke with Robert Mutter, MD, a member of Mayo Clinic Cancer Center in Rochester, Minnesota, about future research for postmastectomy radiotherapy in the treatment of patients with breast cancer.
Shorter Radiation Postmastectomy Induces Similar Complications in Patients With Breast Cancer as Standard Treatment
The use of proton hypofractionated—large doses of radiation given over a shorter period of time than standard radiation—and conventional radiotherapy produced similar complication rates after mastectomy in patients with breast cancer, according to Robert Mutter, MD, a member of Mayo Clinic Cancer Center in Rochester, Minnesota.
Shorter Radiation After Mastectomy Could Improve Access for Patients With Breast Cancer
Hypofractionated proton radiotherapy—large doses of radiation given over a shorter period of time than standard radiation—after mastectomy may lead to greater access for patients with breast cancer, according to an expert from the Mayo Clinic.
Oncology Peer Review On-The-Go: Experts Share Multidisciplinary Takeaways From 2022 SABCS
Judy C. Boughey, MD, Robert Mutter, MD, Siddhartha Yadav, MD, MBBS Judy C. Boughey, MD; Robert Mutter, MD; and Siddhartha Yadav, MD, MBBS, of Mayo Clinic spoke with CancerNetwork® multidisciplinary findings presented at the 2022 San Antonio Breast Cancer Symposium, ranging from surgery to radiotherapy to biomarker research.
Proton Postmastectomy Radiotherapy ‘Should Be a Treatment Option’ for Breast Cancer, Says Expert
Patients should have the option to receive proton postmastectomy radiotherapy for breast cancer when available, according to Robert Mutter, MD, an associate professor of the Department of Radiation Oncology at Mayo Clinic in Rochester, Minnesota.
Optimizing Radiotherapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists
Abstract Immunotherapy using immune checkpoint blockade has revolutionized the treatment of many types of cancer. Radiation therapy (RT)--particularly when delivered at high doses using newer techniques – may be capable of generating systemic anti-tumor effects when combined with immunotherapy in breast cancer. These systemic effects might be due to the local immune-priming effects of RT resulting in the expansion and circulation of effector immune cells to distant sites.
Proton therapy for breast cancer: progress & pitfalls
RW Mutter is supported by the American Society for Radiation Oncology, the National Cancer Institute of the NIH under award number P50CA116201, the Lead Academic Participating Site (LAPS) program under award number 5U10CA180790, K12 HD065987, HALT Cancer at X and the Lawrence W and Marilyn Matteson Fund in Cancer Research. KS Corbin is supported by the Lawrence W and Marilyn Matteson Fund in Cancer Research.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Robert W
Contact Robert W, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack